ArticleFrontiers in pediatrics2026
Repeat kidney biopsy in pediatric lupus nephritis: an analysis of associated clinical-pathological features and outcomes.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Childhood-Onset Lupus Nephritis in the Era of Triple Therapy and Steroid Minimization.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The utility of repeat kidney biopsy in pediatric lupus nephritis (LN) remains debated. This study aims to evaluate pathological evolution, therapeutic implications, and prognostic impact of repeat biopsies in children with LN. Methods: We conducted a retrospective analysis of 19 pediatric LN patients (aged 5-18 years) who underwent ≥2 kidney biopsies at Nanjing Children's Hospital (2009-2022). Pathological classification (ISN/RPS criteria), activity/chronicity indices, and treatment responses were compared between biopsies. Statistical analyses were performed using SPSS 21.0, with Results: The primary indication for repeat biopsy was proteinuria recurrence (73.7%, 14/19). Pathological class transformation occurred in 47.4% (9/19) of cases (e.g., class III to IV), with a higher proportion of non-nephrotic type presentation in the transformation group (77.8% vs. 20.0%, Conclusion: Repeat kidney biopsy detects pathological progression (e.g., increased chronicity) and guides treatment modifications in over 60% of pediatric LN cases. However, pathological class change alone does not dictate short-term outcomes, highlighting initial treatment response as a stronger prognostic indicator. Individualized use of repeat biopsies is recommended for children with proteinuria relapse to optimize management while mitigating procedural invasiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.